ArticleExperimental hematology & oncology2022

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer.

Sophie Cousin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.